Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- IWK Health Centre
- Target Recruit Count
- 100
- Registration Number
- NCT06357234
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Hubei Cancer Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT06080880
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 1028
- Registration Number
- NCT05841849
- Locations
- 🇨🇳
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Hospital General Tlahuac
- Target Recruit Count
- 400
- Registration Number
- NCT05772676
- Locations
- 🇲🇽
Hospital General Tlahuac, Mexico City, Mexico
Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Baskent University
- Target Recruit Count
- 60
- Registration Number
- NCT05632224
- Locations
- 🇹🇷
Baskent University Ankara Hospital, Ankara, Turkey
Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-28
- Target Recruit Count
- 210
- Registration Number
- NCT05346731
- Locations
- 🇷🇺
Zhukov Nikolay, Moscow, Russian Federation
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT04912271
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT04873284
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 80
- Registration Number
- NCT04649229
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Jennifer Holder-Murray
- Target Recruit Count
- 2500
- Registration Number
- NCT04606264
- Locations
- 🇺🇸
UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Passavant, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.